We are live on ! Find out more
ALPN

Alpine Immune Sciences Inc
ALPN

Delisted

ALPN was delisted on the 17th of May, 2024.

Back to rankings

28 hedge funds and large institutions have $24.2M invested in Alpine Immune Sciences Inc in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

9% more capital invested

Capital invested by funds: $22.3M → $24.2M (+$1.93M)

26% less funds holding

Funds holding: 38 → 28 (-10)

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

Holders
28
Holders Change
-10
Holders Change %
-26.32%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
6
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$533K
2
SIM
Spark Investment Management
New York
+$364K
3
RSCM
Rock Springs Capital Management
Maryland
+$281K
4
BlackRock
BlackRock
New York
+$231K
5
ARTA
A.R.T. Advisors
New York
+$156K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.85M
2
KCM
Kingdon Capital Management
New York
-$1.17M
3
AFM
Anson Funds Management
Texas
-$422K
4
PA
Perceptive Advisors
New York
-$274K
5
PAM
Panagora Asset Management
Massachusetts
-$250K
Name Holding Trade Value Shares
Change 		Change in
Stake
TDC
26
Thompson Davis & Co
Virginia
$3K +$2.53K +250 New
MA
27
MUFG Americas
New York
$1K – – –
Wellington Management Group
28
Wellington Management Group
Massachusetts
– -$2.85M -318,064 Closed
KCM
29
Kingdon Capital Management
New York
– -$1.17M -129,978 Closed
AFM
30
Anson Funds Management
Texas
– -$422K -47,072 Closed
PA
31
Perceptive Advisors
New York
– -$274K -30,569 Closed
Goldman Sachs
32
Goldman Sachs
New York
– -$94K -10,533 Closed
SM
33
Sabby Management
Florida
– -$90K -10,001 Closed
RI
34
RTW Investments
New York
– -$67K -7,500 Closed
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
– -$33K -3,646 Closed
VKH
36
Virtu KCG Holdings
New York
– -$33K -3,640 Closed
SIP
37
Stoneridge Investment Partners
Pennsylvania
– -$30K -3,391 Closed
WS
38
Wedbush Securities
California
– -$27K -3,000 Closed
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
– -$16K -1,787 Closed
Barclays
40
Barclays
United Kingdom
– -$9K -1,000 Closed
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
– +$10 +1 New
1
2

ALPN Hedge Fund Activity: Q1 2017 in Review

28 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q1 2017, worth a combined $24.2M — up 8.7% from $22.3M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ALPN and 9 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $533K. The largest seller was Wellington Management Group, exiting entirely with an estimated $2.85M sold.

  • 28 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q1 2017, down from 38 in Q4 2016.
  • Funds reported $24.2M of Alpine Immune Sciences Inc stock for Q1 2017, up 8.7% quarter-over-quarter.
  • 9 funds opened new Alpine Immune Sciences Inc positions in Q1 2017 and 13 closed out, a net change of -4 holders.
  • The largest Alpine Immune Sciences Inc buyer in Q1 2017 was Vanguard Group, an estimated $533K added.
  • The largest Alpine Immune Sciences Inc seller in Q1 2017 was Wellington Management Group, an estimated $2.85M sold.

Based on aggregated 13F filings for Q1 2017.